INTRODUCTION
Pre-exposure prophylaxis (PrEP) is defined as the use of antiretroviral drugs to prevent human immunodeficiency virus (HIV) acquisition by uninfected individuals. 1 The high efficacy of oral PrEP in both continuous and event-driven regimens has been demonstrated in several trials, [2] [3] [4] [5] [6] [7] [8] as has its cost-effectiveness with each avoided infection. 9, 10 In 2015 the World Health Organization (WHO) recommended PrEP as a prevention tool for serodiscordant couples, transgender women and men who have sex with men at high risk of HIV 11 after first publishing guidance on PrEP use in demonstration projects in 2012 -the same year the Food and Drug Administration (FDA) approved emtricitabine/tenofovir disoproxil fumarate for PrEP in the USA. 12 Formal introduction of PrEP in the European Union was led by France in December 2015, with authorization and full reimbursement for people at high risk of acquiring HIV, and the launch of hospital-based PrEP consultations in Paris in January 2016. 13 Norway, Scotland and Belgium soon joined France in implementing PrEP delivery across their respective national health services (NHS). A second group of countries began providing PrEP within the scope of small demonstration projects, which are currently at full recruiting capacity (e.g. England and Spain). 14 A third group of countries made the medicines for PrEP available at community pharmacies, but struggle with warranting reimbursement by insurers (e.g. Netherlands and Germany). 14 Portugal approved PrEP on the 2 nd June 2017, under the terms of Dispatch 4835/2017 of the Deputy Secretary of Health, 15 joining France's model of provision from the NHS. On the 28 th November 2017 the General Directorate for Health published a novel clinical guideline on PrEP, 16 stipulating that people at increased risk of acquiring HIV be referred to a hospital specialist within 30 days. On the 21 st February 2018 the National Authority of Medicines and Health Products, (INFARMED) approved an Early Access Program for the provision of emtricitabine/tenofovir disoproxil fumarate for use in association with safer sex practices as PrEP, free of charge in the NHS, in order to accelerate access to these medicines in the anticipation of the still ongoing reimbursement approval process. 17 The first patient appointment for PrEP took place on the 12 th April 2018, 11 months after its ministerial approval. At the moment of publication, PrEP was available in 6 of the 44 Portuguese NHS hospitals, in the cities of Almada, Lisbon, Loures and Porto, some of which have been unable to comply with the maximum compulsory 30-day response period. PrEP is not available for migrant citizens not yet enrolled in the NHS.
PrEP was informally in use in European countries prior to formal introduction, and outside the context of clinical trials and demonstration projects, in a still ongoing phenomena dubbed 'Wild PrEP', resembling the antiretroviral buyers' clubs of the 1980s. [18] [19] [20] [21] [22] [23] [24] [25] Medicines for PrEP can currently be obtained informally in several ways: by ordering them online; by purchasing them where the medicines are available over the counter; by seeking faux post-exposure prophylaxis (PEP) care; 23 or by using medicines prescribed to people living with HIV. Informal PrEP poses significant challenges for health care professionals and health services, as it does not ensure access to adequate follow up, 26 and it is difficult to control the quality of medicines ordered online, which can in extremis result in the user acquiring an HIV infection.
Studies published in recent years have provided valuable insights into the factors underlying PrEP use, showing delivery models play a considerable role in shaping the strategy's success. Interventions have been considered more effective when offered in combination with comprehensive prevention approaches, 1 and the use of a wide range of health care professionals has also been shown to improve medication adherence. 27 Furthermore, studies suggest PrEP services should be planned with consideration for user preferences, namely by offering them at convenient times and in welcoming settings, such as Public Health Services or STI clinics with experience regarding PrEP care and cultural awareness in dealing with vulnerable populations. 28 Few healthcare services in Portugal cater to the needs of the populations at most risk of acquiring HIV. CheckpointLX is a community-based sexual health center managed by Grupo de Ativistas em Tratamentos/Group of Activists in Treatments (GAT), a non-governmental organization that advocates for legal and political reforms that drive positive changes for people living with HIV and for those at risk of acquiring the infection. CheckpointLX is one of the few STI clinics targeted at MSM in Portugal, working as a low threshold walk-in clinic offering rapid testing for blood-borne viruses and syphilis, and as an outpatient clinic for screening and treatment of other STIs. While other STI clinics exist, they target the general population, which some regard as an access barrier to MSM sexual health services for fear of stigma and discrimination.
On May 12 2015, recognizing the increasing use of informal PrEP, CheckpointLX began offering counselling and follow-up services for MSM prior to formal introduction. When PrEP was approved in Portugal, CheckpointLX continued to offer counselling for PrEP with the aim of screening high risk HIV negative MSM and referring them to PrEP in the NHS.
This study aims to characterize PrEP users attending CheckpointLX before formal PrEP introduction in Portugal, and those who were referred to PrEP in the NHS after screening at CheckpointLX.
MATERIAL AND METHODS
Data were collected by qualified peer counsellors and inserted in a database, including sociodemographic data, behavioral characteristics, immunization and prior STI testing records, and other data connected with PrEP follow up. 29 Medical care followed European AIDS Clinical Society (EACS) recommendations for PrEP eligibility, initiation and follow up. For formal PrEP, the General-Directorate for Health's PrEP guidelines checklist was used. 28 Table 1 summarizes the criteria of this checklist, as well as other clinical evaluation and preventive measures to be taken prior to PrEP initiation. For the purpose of this study, we considered two populations: Wild PrEP (data collected from May 2015 until May 2018) and formal PrEP (data collected from May 2018 to September 2018). Between April and May there was an overlap for both populations.
Data collection and utilization were authorized by the Portuguese Data Protection Commission (authorization no.3207/2017). Data were analyzed using STATA(R) version 13.
RESULTS
From May 2015 until the end of May 2018, prior to the introduction of formal PrEP in Portugal, CheckpointLX had a total of 90 appointments for Wild PrEP, of which 64 (71%) were first time visits and the remaining were follow up visits. Most service users were born in Portugal (n = 41, 64%), while 7 (11%) were from Brazil. The mean age was 40 years old (SD 9.5 years) and almost all (n = 58, 91%) self-identified as homosexual. With regards to immunization status, 41 (64%) were vaccinated against Hepatitis B virus at admission, 24 (38%) were vaccinated against Hepatitis A virus and 7 (11%) were vaccinated against Human Papillo-ma Virus with either quadrivalent or 9-valent vaccines. Out of the the total, 24 (38%) had a self-reported history of an STI in the past 12-month period, syphilis being the most common (n = 9, 38%). Most (n = 40, 63%) reported more than 10 sexual partners over the past 12-month period, and 35 (55%) had at least one instance of sex with multiple partners in the same period. Inhaled drug use was reported by 33 (52%) service users. Table 2 summarizes the baseline characteristics of service users in follow-up of 'Wild PrEP' at CheckpointLX.
As for the 380 service users referred to the NHS following formal introduction of PrEP, most were Portuguese (n = 318, 84%), and the mean age was 31 (8.9) years old. Eligibility criteria was available for a subset of 71 users, 58% of whom fulfilled 1 criterion only, followed by 30% who fulfilled 2 criteria. Condomless sex in the last six months with partners of unknown HIV status was the most common eligibility criteria (n = 59, 83%), followed by sex under the influence of alcohol and drugs (n = 25, 35%). Table 3 shows the baseline characteristics of users referred to PrEP in the NHS from April 2018 to September 2018.
DISCUSSION
CheckpointLX's three-year long experience providing follow up medical care for Wild PrEP users represents an invaluable opportunity to study this population closely and learn more about their needs and requirements.
A total of 97% of Wild PrEP users had been tested for HIV in the past three months, showing most were seeking follow up care at adequate intervals. 38% had an STI diagnosis in the past 12-month period, 63% reported having 10 or more sexual partners and 73% reported inconsistent condom use in the same period, attesting to their high risk of acquiring HIV. This last item was similar in users referred to formal PrEP, 83% of whom reported instances of condomless sex in the last six months with people of unknown HIV status as their main criteria for seeking PrEP. While a good number of users were immunized against Hepatitis B (64%), only a fraction was immunized against Hepatitis A (38%) or HPV (11%). Considering this population's highest risk of infection with both viruses and recent viral hepatitis outbreaks in Europe, including Portugal, 30 it is crucial to complement PrEP delivery with effective information regarding the importance of immunization in the scope of broader preventive sexual health care. Given that 52% reported inhaled drug use in the past 12-month period, it is safe to assume harm reduction interventions are also needed, such as education regarding safer practices of drug use.
All criterion of eligibility (as per General-Directorate for Health guideline)

Condomless sex in the last six months with partner of unknow HIV status
Condomless sex and an STI diagnosis in the last six months
A total of 36% of CheckpointLX's Wild PrEP users are foreign citizens living in Portugal, yet only 16% of those referred for formal PrEP in the NHS were foreign citizens. There is enough data to show an unmet need in providing formal PrEP for migrant citizens. Including these citizens in any future update to public health policy will be crucial, for risk of failure of the strategy, as borders may apply to provision but not to disease control.
This study has some limitations which should be mentioned. One is recall bias, as participants might not remember accurately all the information that is asked to them during the interview. The interviewer bias is also to consider: the respondents might want to please the interviewer by giving him the information they consider appropriate. External validity of this study might be limited due to the fact that participants are recruited might not be representative of the MSM population in Lisbon.
Even though efforts have been made towards offering PrEP to the Portuguese population, much remains to be done to ensure that PrEP is available to those in need. A study conducted by the CDC using a national representative sample from the United States of America estimated that 24.5% of sexually active MSM, 18.5% of people who inject drugs and 0.4% of sexually active heterosexual individuals were eligible for PrEP. 31 According to data from the Lisbon MSM cohort (n = 5,447), a variable number of MSM would be eligible for PrEP in Portugal: 2485 (45.6%) according to EACS 2017 guidelines, 2929 (53.8%), according to WHO 2017 guidelines, and 3556 (65.3%) according to CDC 2014 guidelines. 33 This is far above the current capacity of the Portuguese NHS, which demonstrates the scale up and diversification need of the current pilot.
PrEP should also be made available at the community level, as a complement to hospital delivery, as it can increase the availability and uptake of PrEP. A combination of other key elements for successful PrEP implementation have been identified by a review on PrEP implementation in early adopting countries and should be considered in Portugal. 34 These include: knowledge of the epidemiology and patterns of HIV transmission, determination of the facilities which are best equipped for PrEP delivery, community engagement, institutional leadership, training of providers and the community and adequate access to related health services, including STI screening and management, harm reduction programs and behavioral health interventions.
CONCLUSION
To the best of our knowledge, our study is the first to describe the use of PrEP in MSM in Portugal, providing an overview of the use of Wild PrEP and also the use of PrEP following the formal introduction of PrEP in the NHS. Despite recent steps to implement PrEP in Portugal, much remains to be done to ensure adequate access and follow up for those who stand to benefit most from this prevention strategy, namely: scale up of capacity, diversification of sites of PrEP care provision, inclusion of migrant citizens, investment in harm reduction and in vaccination. 
